Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties.

Carroll KN, Griffin MR, Edwards KM, Ali A, Zhu Y, Iwane MK, Szilagyi PG, Staat MA, Stevens TP, Hall CB, Williams JV, Hartert TV
Pediatr Infect Dis J. 2012 31 (11): e229-31

PMID: 22760537 · PMCID: PMC3773819 · DOI:10.1097/INF.0b013e318266bf89

Among infants with prematurity and/or chronic lung disease for whom respiratory syncytial virus immunoprophylaxis is recommended, we examined adherence in infants enrolled during healthcare visits for acute respiratory illness in 3 U.S. counties from 2001 to 2007. Immunoprophylaxis among infants who met national criteria for prophylaxis increased from 33% to 83% over the 6-year period; 17% (11/65) of infants who received immunoprophylaxis did not meet eligibility criteria.

MeSH Terms (12)

Antibodies, Monoclonal, Humanized Antiviral Agents Chronic Disease Humans Infant Infant, Newborn Infant, Premature Palivizumab Practice Guidelines as Topic Respiratory Syncytial Virus Infections Time Factors United States

Connections (3)

This publication is referenced by other Labnodes entities: